Blueprint Medicines (BPMC) Financials

$103.00 +1.79 (+1.77%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for Blueprint Medicines

This table shows Blueprint Medicines' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-67	-507	-558	-644	314	-348	-237	-148	-72	-56
Consolidated Net Income / (Loss)	-67	-507	-558	-644	314	-348	-237	-148	-72	-53
Net Income / (Loss) Continuing Operations	-66	-507	-558	-644	314	-348	-237	-148	-72	-53
Total Pre-Tax Income	-66	-506	-552	-641	315	-348	-237	-148	-72	-53
Total Operating Income	-212	-486	-538	-642	309	-361	-247	-151	-73	-52
Total Gross Profit	489	241	186	162	793	67	45	21	28	11
Total Revenue	509	249	204	180	794	67	45	21	28	11
Operating Revenue	509	249	204	180	794	67	45	21	28	11
Total Cost of Revenue	20	8.54	18	18	0.43	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	20	8.54	18	18	0.43	0.00	0.00	-	-	-
Total Operating Expenses	701	727	724	822	485	428	292	173	100	63
Selling, General & Admin Expense	359	295	237	195	158	96	48	28	19	14
Research & Development Expense	341	428	477	601	327	331	244	145	81	49
Other Operating Expenses / (Income)	0.00	4.26	8.95	7.80	0.00	0.00	-	-	-	-
Total Other Income / (Expense), net	146	-20	-15	0.90	6.23	14	10	3.13	0.08	-1.13
Interest Expense	-174	0.00	0.00	-2.39	-6.60	-14	-11	-3.20	0.47	0.70
Interest & Investment Income	-28	-19	-17	-	-	-	-	-	-	-
Income Tax Expense	1.23	0.97	5.24	3.00	1.06	0.00	0.00	-	-	-
Other Gains / (Losses), net	0.66	-	-	-	-	-	-	-	-	-
Basic Earnings per Share	($1.07)	($8.37)	($9.35)	($11.01)	$5.76	($7.27)	($5.39)	($3.92)	($2.64)	-
Weighted Average Basic Shares Outstanding	62.86M	60.56M	59.64M	58.52M	54.53M	47.83M	43.87M	37.79M	27.49M	18.24M
Diluted Earnings per Share	($1.07)	($8.37)	($9.35)	($11.01)	$5.59	($7.27)	($5.39)	($3.92)	($2.64)	-
Weighted Average Diluted Shares Outstanding	62.86M	60.56M	59.64M	58.52M	56.17M	47.83M	43.87M	37.79M	27.49M	18.24M
Weighted Average Basic & Diluted Shares Outstanding	63.91M	61.23M	59.98M	59.20K	54.53M	47.83M	43.87M	37.79M	27.49M	18.24M

This table shows Blueprint Medicines' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	0.50	-53	-53	-50	89	-113	-132	-132	-130	-159	-133
Consolidated Net Income / (Loss)	0.50	-50	-56	-50	89	-111	-134	-133	-130	-159	-133
Net Income / (Loss) Continuing Operations	0.50	-49	-56	-50	89	-111	-134	-133	-130	-159	-133
Total Pre-Tax Income	1.29	-49	-56	-50	89	-111	-134	-133	-129	-158	-132
Total Operating Income	-41	-41	-49	-43	-79	-105	-129	-128	-124	-150	-124
Total Gross Profit	147	139	126	131	93	72	54	55	60	34	63
Total Revenue	149	146	128	138	96	72	57	58	63	39	66
Operating Revenue	149	146	128	138	96	72	57	58	63	39	66
Total Cost of Revenue	2.80	7.45	1.93	7.59	3.19	0.26	2.78	2.32	3.18	4.85	3.00
Operating Cost of Revenue	2.80	7.45	1.93	7.59	3.19	0.26	2.78	2.32	3.18	4.85	3.00
Total Operating Expenses	188	180	175	174	172	177	183	183	184	184	187
Selling, General & Admin Expense	96	96	90	89	84	82	71	72	71	64	58
Research & Development Expense	92	84	85	84	88	95	110	110	112	118	128
Total Other Income / (Expense), net	42	-8.08	-7.03	-6.85	168	-5.75	-4.54	-4.62	-4.83	-7.81	-8.00
Interest Expense	0.00	-5.90	0.00	-0.02	-168	-5.82	0.00	0.00	5.82	-7.53	8.40
Interest & Investment Income	-8.13	-	-7.62	-6.86	-	-	-3.81	-4.00	-	-	-
Other Income / (Expense), net	51	-	0.59	-0.00	0.38	-0.58	-0.73	-0.63	0.99	1.43	0.40
Income Tax Expense	0.79	0.67	0.27	0.10	0.18	0.06	0.20	0.19	0.52	1.04	0.89
Basic Earnings per Share	$0.01	($0.83)	($0.89)	($0.80)	$1.45	($1.83)	($2.20)	($2.19)	($2.15)	($2.65)	($2.23)
Weighted Average Basic Shares Outstanding	64.10M	62.86M	63.38M	62.85M	61.58M	60.56M	60.69M	60.52M	60.13M	59.64M	59.76M
Diluted Earnings per Share	$0.01	($0.78)	($0.89)	($0.80)	$1.40	($1.83)	($2.20)	($2.19)	($2.15)	($2.65)	($2.23)
Weighted Average Diluted Shares Outstanding	66.53M	62.86M	63.38M	62.85M	63.80M	60.56M	60.69M	60.52M	60.13M	59.64M	59.76M
Weighted Average Basic & Diluted Shares Outstanding	64.58M	63.91M	63.53M	63.35M	62.62M	61.23M	60.79M	60.66M	60.47M	59.98M	59.83M

This table details how cash moves in and out of Blueprint Medicines' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	33	-44	-90	-474	571	46	-332	352	-111	115
Net Cash From Operating Activities	-193	-437	-502	-299	387	-278	-175	-120	-25	-32
Net Cash From Continuing Operating Activities	-193	-437	-502	-299	387	-278	-175	-120	-25	-32
Net Income / (Loss) Continuing Operations	-67	-507	-558	-644	314	-348	-237	-148	-72	-53
Consolidated Net Income / (Loss)	-67	-507	-558	-644	314	-348	-237	-148	-72	-53
Depreciation Expense	16	12	12	6.48	6.56	5.26	4.25	1.58	1.58	0.95
Amortization Expense	-22	-17	-0.98	1.36	-	-	-	-	-	0.11
Non-Cash Adjustments To Reconcile Net Income	-54	129	92	364	86	32	26	16	6.44	5.63
Changes in Operating Assets and Liabilities, net	-66	-53	-47	-27	-20	32	31	11	40	14
Net Cash From Investing Activities	-48	274	-150	-226	-434	-16	-161	-72	-219	-6.08
Net Cash From Continuing Investing Activities	-48	274	-150	-226	-434	-16	-161	-72	-219	-6.08
Purchase of Property, Plant & Equipment	-4.63	-16	-8.92	-3.09	-3.16	-14	-13	-16	-2.35	-4.88
Purchase of Investments	-966	-766	-490	-655	-969	-738	-801	-361	-264	0.00
Sale and/or Maturity of Investments	924	1,056	349	691	538	736	653	304	48	0.00
Other Investing Activities, net	0.00	0.00	-0.29	0.00	0.00	-	-	-	-	-1.20
Net Cash From Financing Activities	273	119	562	51	618	341	4.45	544	133	153
Net Cash From Continuing Financing Activities	273	119	562	51	618	341	4.45	544	133	153
Repayment of Debt	146	98	554	0.00	0.00	-0.12	-1.97	-2.58	-3.33	-1.81
Issuance of Common Equity	49	0.00	0.00	-	582	327	0.00	547	136	157
Other Financing Activities, net	78	21	8.20	51	35	13	6.43	-	-	-
Cash Interest Paid	80	38	9.81	0.00	0.00	-	0.27	0.15	0.32	0.45
Cash Income Taxes Paid	1.10	-0.05	6.51	0.69	0.78	0.19	0.12	0.04	-	-

This table details how cash moves in and out of Blueprint Medicines' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	20	14	35	-58	43	15	-16	-93	50	-172	118
Net Cash From Operating Activities	-54	-29	-14	-48	-102	-79	-104	-130	-123	-121	-130
Net Cash From Continuing Operating Activities	-54	-29	-14	-48	-102	-79	-104	-130	-123	-121	-130
Net Income / (Loss) Continuing Operations	0.50	-50	-56	-50	89	-111	-134	-133	-130	-159	-133
Consolidated Net Income / (Loss)	0.50	-50	-56	-50	89	-111	-134	-133	-130	-159	-133
Depreciation Expense	4.46	4.00	3.86	3.62	4.81	1.53	2.87	3.58	3.68	7.02	1.62
Amortization Expense	-3.33	-5.29	-6.33	-5.65	-5.19	-5.94	-5.44	-3.71	-2.38	-1.83	-
Non-Cash Adjustments To Reconcile Net Income	-18	31	30	31	-146	40	29	30	30	23	6.79
Changes in Operating Assets and Liabilities, net	-38	-9.59	15	-27	-44	-3.85	2.84	-27	-25	9.46	-5.99
Net Cash From Investing Activities	65	34	30	-188	77	79	-9.59	32	173	-53	-132
Net Cash From Continuing Investing Activities	65	34	30	-188	77	79	-9.59	32	173	-53	-132
Purchase of Property, Plant & Equipment	-1.83	-0.93	-0.03	-2.57	-1.10	-4.67	-6.25	-2.55	-2.58	-1.48	-3.73
Purchase of Investments	-283	-210	-201	-355	-200	-118	-241	-275	-133	-231	-219
Sale and/or Maturity of Investments	350	244	231	170	278	201	238	310	308	179	91
Net Cash From Financing Activities	9.19	9.76	18	178	67	16	98	5.30	0.00	2.49	381
Net Cash From Continuing Financing Activities	9.19	9.76	18	178	67	16	98	5.30	0.00	2.49	381
Repayment of Debt	-4.11	-	-	147	-0.37	-0.08	98	-	0.00	-0.02	-
Issuance of Common Equity	0.00	-	-	-	49	-	-	-	0.00	-	-
Other Financing Activities, net	13	9.76	18	31	18	16	0.43	5.30	0.00	2.51	1.92
Cash Interest Paid	21	24	23	18	14	13	10	8.08	7.08	6.86	2.96
Cash Income Taxes Paid	0.70	0.32	0.24	0.03	0.52	-0.81	0.09	0.37	0.31	2.49	3.25

This table presents Blueprint Medicines' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	1,180	1,049	1,350	1,252	1,718	708	540	716	283	179
Total Current Assets	743	808	1,047	554	928	517	500	686	220	170
Cash & Equivalents	102	71	120	210	685	114	68	400	52	163
Short-Term Investments	513	639	825	267	187	370	426	273	162	0.00
Accounts Receivable	76	43	24	25	7.10	0.66	0.06	-	-	3.41
Inventories, net	14	21	30	22	8.58	0.00	-	-	-	-
Prepaid Expenses	36	33	35	18	22	9.82	5.56	12	2.69	4.18
Other Current Assets	1.81	0.35	13	12	18	23	0.15	-	3.58	-
Plant, Property, & Equipment, net	37	42	33	31	34	38	30	24	6.19	6.66
Total Noncurrent Assets	401	199	270	668	757	153	11	5.87	56	1.82
Long-Term Investments	248	57	133	558	678	64	0.00	-	54	0.00
Other Noncurrent Operating Assets	152	142	136	110	79	88	11	5.87	0.86	0.56
Total Liabilities & Shareholders' Equity	1,180	1,049	1,350	1,252	1,718	708	540	716	283	179
Total Liabilities	881	919	835	281	248	243	121	92	70	35
Total Current Liabilities	261	215	183	150	131	106	60	43	29	19
Short-Term Debt	44	30	17	-	-	-	-	1.52	2.55	3.27
Accounts Payable	6.79	4.71	2.73	8.33	4.37	4.79	3.30	3.74	2.21	2.46
Accrued Expenses	133	128	131	122	106	89	52	31	12	6.44
Current Deferred Revenue	64	40	4.67	12	13	6.16	3.60	5.37	11	5.90
Other Current Liabilities	13	12	28	8.09	7.94	6.82	1.71	1.71	0.58	0.58
Total Noncurrent Liabilities	620	704	652	132	118	137	61	49	41	16
Long-Term Debt	537	611	535	-	-	-	-	-	1.52	4.07
Capital Lease Obligations	69	82	-	-	-	-	13	15	2.79	3.37
Noncurrent Deferred Revenue	8.19	4.79	14	25	29	40	48	34	37	8.58
Other Noncurrent Operating Liabilities	6.79	6.21	103	107	89	97	0.19	0.13	0.15	0.25
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	299	131	515	971	1,470	464	419	624	213	144
Total Preferred & Common Equity	299	131	515	971	1,470	464	419	624	213	144
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	299	131	515	971	1,470	464	419	624	213	144
Common Stock	2,709	2,474	2,358	2,250	2,107	1,412	1,017	980	421	279
Retained Earnings	-2,407	-2,340	-1,833	-1,275	-631	-945	-598	-356	-207	-135
Accumulated Other Comprehensive Income / (Loss)	-3.55	-3.50	-10	-4.13	-5.21	-2.54	-0.18	-0.27	-0.02	0.00

This table presents Blueprint Medicines' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,196	1,200	1,204	1,038	1,105	1,106	1,220	1,458
Total Current Assets	702	855	904	777	808	811	900	1,228
Cash & Equivalents	122	89	55	113	56	76	170	291
Short-Term Investments	454	645	709	535	657	647	652	846
Accounts Receivable	78	66	85	60	41	38	31	19
Inventories, net	13	13	15	31	16	17	18	35
Prepaid Expenses	33	42	40	38	37	33	29	34
Other Current Assets	1.72	-	-	-	-	-	-	2.60
Plant, Property, & Equipment, net	36	38	40	42	41	37	34	33
Total Noncurrent Assets	457	307	260	220	257	258	286	197
Long-Term Investments	324	148	105	88	114	114	139	56
Other Noncurrent Operating Assets	134	159	155	132	142	144	147	142
Total Liabilities & Shareholders' Equity	1,196	1,200	1,204	1,038	1,105	1,106	1,220	1,458
Total Liabilities	853	887	883	728	903	795	806	818
Total Current Liabilities	251	258	244	207	197	169	173	176
Short-Term Debt	44	45	48	30	30	18	17	15
Accounts Payable	0.80	4.72	4.86	4.93	6.96	6.98	11	4.23
Accrued Expenses	122	131	121	107	110	101	109	121
Current Deferred Revenue	70	64	57	52	38	32	25	4.63
Other Current Liabilities	14	13	13	12	12	11	11	31
Total Noncurrent Liabilities	603	629	640	521	705	626	633	643
Long-Term Debt	523	543	550	432	613	531	535	526
Capital Lease Obligations	65	72	75	78	84	87	90	-
Noncurrent Deferred Revenue	8.04	7.92	8.04	4.64	5.00	5.00	5.00	12
Other Noncurrent Operating Liabilities	6.97	6.17	5.78	5.77	3.10	3.16	3.10	104
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	342	313	320	311	203	311	414	640
Total Preferred & Common Equity	342	313	320	311	203	311	414	640
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	342	313	320	311	203	311	414	640
Common Stock	2,752	2,671	2,625	2,565	2,434	2,411	2,381	2,329
Retained Earnings	-2,407	-2,357	-2,301	-2,251	-2,229	-2,095	-1,963	-1,674
Accumulated Other Comprehensive Income / (Loss)	-3.24	-1.07	-3.89	-3.85	-2.68	-4.22	-4.60	-15

This table displays calculated financial ratios and metrics derived from Blueprint Medicines' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	104.04%	22.22%	13.30%	-77.31%	1,093.37%	49.39%	107.79%	-22.85%	143.61%	0.00%
EBITDA Growth	55.74%	6.05%	17.44%	-301.85%	188.41%	-46.59%	-62.25%	-112.57%	-38.08%	-30.39%
EBIT Growth	56.48%	9.02%	16.78%	-308.69%	185.31%	-46.20%	-63.36%	-110.10%	-38.32%	-30.73%
NOPAT Growth	56.39%	9.53%	16.27%	-246.06%	221.64%	-46.27%	-63.33%	-108.40%	-40.53%	-29.97%
Net Income Growth	86.77%	9.06%	13.44%	-305.20%	190.28%	-46.93%	-59.76%	-104.32%	-37.38%	-30.99%
EPS Growth	87.22%	10.48%	15.08%	-296.96%	176.89%	-34.88%	-37.50%	-48.48%	0.00%	0.00%
Operating Cash Flow Growth	55.91%	13.03%	-68.18%	-177.16%	239.21%	-58.86%	-46.01%	-388.99%	22.61%	10.52%
Free Cash Flow Firm Growth	66.70%	-2.33%	7.87%	-253.15%	231.23%	-60.63%	-17.93%	-1,045.73%	64.10%	-19.50%
Invested Capital Growth	-2.80%	840.80%	81.74%	19.75%	4.75%	-34.62%	-86.76%	32.89%	-426.80%	-217.95%
Revenue Q/Q Growth	17.13%	15.34%	-25.06%	68.04%	-2.15%	315.39%	-1.32%	-22.06%	12.36%	68.51%
EBITDA Q/Q Growth	23.39%	6.29%	24.74%	-56.41%	-4.98%	5.83%	-18.41%	-26.36%	-8.94%	-1.93%
EBIT Q/Q Growth	23.05%	8.05%	23.90%	-55.85%	-5.11%	5.65%	-18.47%	-26.01%	-8.69%	-2.15%
NOPAT Q/Q Growth	23.16%	8.42%	23.63%	-55.89%	-5.42%	3.67%	-15.45%	-23.44%	-8.93%	-2.23%
Net Income Q/Q Growth	47.61%	8.60%	22.30%	-56.69%	-5.80%	3.87%	-15.24%	-23.07%	-8.51%	-2.14%
EPS Q/Q Growth	49.53%	8.92%	22.92%	-62.87%	2.57%	6.44%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	20.47%	8.86%	-27.16%	3.45%	5.48%	7.54%	-23.09%	-15.35%	-30.65%	-4.85%
Free Cash Flow Firm Q/Q Growth	19.30%	9.64%	18.94%	-67.63%	7.29%	4.04%	-5.20%	-35.52%	-5.90%	0.00%
Invested Capital Q/Q Growth	-7.26%	-15.93%	-7.94%	-36.82%	-121.82%	-7.02%	-9.46%	24.25%	-2.63%	19.66%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	96.04%	96.58%	91.27%	90.04%	99.95%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-42.89%	-197.70%	-257.19%	-352.97%	39.67%	-535.49%	-545.72%	-698.89%	-253.65%	-447.51%
Operating Margin	-41.67%	-194.99%	-263.44%	-356.50%	38.89%	-543.25%	-554.86%	-705.90%	-261.33%	-453.02%
EBIT Margin	-41.67%	-195.37%	-262.46%	-357.32%	38.85%	-543.40%	-555.26%	-706.26%	-259.35%	-456.78%
Profit (Net Income) Margin	-13.19%	-203.30%	-273.24%	-357.67%	39.54%	-522.75%	-531.53%	-691.31%	-261.04%	-462.89%
Tax Burden Percent	101.86%	100.19%	100.95%	100.47%	99.66%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	31.06%	103.86%	103.13%	99.63%	102.14%	96.20%	95.73%	97.88%	100.65%	101.34%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.34%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-174.17%	-910.61%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-237.03%	-852.21%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	142.92%	753.47%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-31.26%	-157.13%	-75.07%	-52.78%	32.45%	-78.72%	-45.38%	-35.39%	-40.61%	-58.83%
Cash Return on Invested Capital (CROIC)	-171.34%	-507.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-19.03%	-40.62%	-41.16%	-43.32%	25.42%	-57.93%	-39.37%	-30.31%	-31.20%	-45.51%
Return on Assets (ROA)	-6.02%	-42.26%	-42.85%	-43.36%	25.88%	-55.73%	-37.69%	-29.67%	-31.40%	-46.12%
Return on Common Equity (ROCE)	-31.26%	-157.13%	-75.07%	-52.78%	32.45%	-78.72%	-45.38%	-35.39%	-40.61%	-21.18%
Return on Equity Simple (ROE_SIMPLE)	-22.46%	-388.17%	-108.32%	-66.35%	21.35%	-74.88%	-56.48%	-23.74%	-34.02%	-36.65%
Net Operating Profit after Tax (NOPAT)	-148	-340	-376	-449	308	-253	-173	-106	-51	-36
NOPAT Margin	-29.17%	-136.50%	-184.41%	-249.55%	38.76%	-380.27%	-388.40%	-494.13%	-182.93%	-317.11%
Net Nonoperating Expense Percent (NNEP)	62.85%	-58.40%	-23.22%	-15.07%	0.59%	-18.42%	-11.20%	-9.19%	-10.43%	-17.33%
Return On Investment Capital (ROIC_SIMPLE)	-15.66%	-39.88%	-35.27%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	3.96%	3.42%	8.73%	9.96%	0.05%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	70.61%	118.35%	116.34%	108.45%	19.87%	144.92%	107.65%	130.62%	69.20%	126.81%
R&D to Revenue	67.10%	171.51%	233.99%	333.76%	41.18%	498.33%	547.20%	675.29%	292.13%	426.21%
Operating Expenses to Revenue	137.71%	291.57%	354.71%	456.50%	61.05%	643.25%	654.86%	805.90%	361.33%	553.02%
Earnings before Interest and Taxes (EBIT)	-212	-487	-536	-643	308	-361	-247	-151	-72	-52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-218	-493	-525	-636	315	-356	-243	-150	-70	-51
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	18.55	42.93	5.09	6.49	4.25	8.49	5.65	4.74	3.60	4.96
Price to Tangible Book Value (P/TBV)	18.55	42.93	5.09	6.49	4.25	8.49	5.65	4.74	3.60	4.96
Price to Revenue (P/Rev)	10.89	22.48	12.85	35.00	7.87	59.26	53.22	137.98	27.60	62.62
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	19.91	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	5.02%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	63.40	64.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	10.47	22.31	10.27	29.25	5.92	51.02	42.41	107.30	18.19	49.27
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	14.93	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	15.24	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	15.28	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	12.14	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	15.48	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	2.17	5.54	1.07	0.00	0.00	0.00	0.03	0.03	0.03	0.07
Long-Term Debt to Equity	2.03	5.30	1.04	0.00	0.00	0.00	0.03	0.02	0.02	0.05
Financial Leverage	-0.60	-0.88	-1.05	-1.06	-1.08	-1.16	-1.09	-1.10	-1.17	-1.07
Leverage Ratio	5.19	3.72	1.75	1.22	1.25	1.41	1.20	1.19	1.29	1.28
Compound Leverage Factor	1.61	3.86	1.81	1.21	1.28	1.36	1.15	1.17	1.30	1.29
Debt to Total Capital	68.49%	84.70%	51.76%	0.00%	0.00%	0.00%	2.99%	2.52%	3.12%	6.92%
Short-Term Debt to Total Capital	4.63%	3.55%	1.58%	0.00%	0.00%	0.00%	0.00%	0.24%	1.16%	2.11%
Long-Term Debt to Total Capital	63.86%	81.15%	50.18%	0.00%	0.00%	0.00%	2.99%	2.28%	1.96%	4.81%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	31.51%	15.30%	48.24%	100.00%	100.00%	100.00%	97.01%	97.48%	96.88%	93.08%
Debt to EBITDA	-2.98	-1.47	-1.05	0.00	0.00	0.00	-0.05	-0.11	-0.10	-0.21
Net Debt to EBITDA	0.98	0.09	1.00	0.00	0.00	0.00	1.98	4.39	3.71	2.98
Long-Term Debt to EBITDA	-2.77	-1.41	-1.02	0.00	0.00	0.00	-0.05	-0.10	-0.06	-0.15
Debt to NOPAT	-4.37	-2.12	-1.47	0.00	0.00	0.00	-0.07	-0.15	-0.14	-0.30
Net Debt to NOPAT	1.45	0.13	1.40	0.00	0.00	0.00	2.78	6.21	5.14	4.21
Long-Term Debt to NOPAT	-4.08	-2.04	-1.42	0.00	0.00	0.00	-0.07	-0.14	-0.08	-0.21
Altman Z-Score	1.24	-0.08	-0.41	10.84	16.20	6.95	9.74	19.04	5.64	11.33
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	63.99%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.85	3.76	5.71	3.70	7.09	4.85	8.29	15.98	7.73	9.14
Quick Ratio	2.65	3.51	5.29	3.35	6.72	4.55	8.19	15.70	7.51	8.91
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-146	-438	-429	-465	304	-231	-144	-122	-11	-30
Operating Cash Flow to CapEx	-4,159.52%	-2,719.75%	-5,631.54%	-9,668.27%	12,251.82%	-1,983.98%	-1,380.52%	-772.72%	-1,041.33%	-648.70%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-22.74	-42.68
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-52.27	-45.51
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-57.29	-52.53
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.46	0.21	0.16	0.12	0.65	0.11	0.07	0.04	0.12	0.10
Accounts Receivable Turnover	8.58	7.52	8.38	11.17	204.60	182.98	0.00	0.00	0.00	0.00
Inventory Turnover	1.16	0.34	0.69	1.18	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	12.96	6.62	6.37	5.56	21.90	1.96	1.65	1.40	4.32	2.80
Accounts Payable Turnover	3.51	2.30	3.22	2.82	0.09	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	42.55	48.56	43.54	32.68	1.78	1.99	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	315.29	1,088.16	527.78	309.34	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	104.09	158.97	113.33	129.27	3,934.70	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	253.75	977.75	457.99	212.75	-3,932.92	1.99	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	84	86	-12	-64	-80	-84	-62	-33	-50	-9.41
Invested Capital Turnover	5.97	6.67	-5.40	-2.51	-9.73	-0.91	-0.93	-0.52	-0.94	-1.84
Increase / (Decrease) in Invested Capital	-2.42	98	52	16	3.97	-22	-29	16	-40	-6.45
Enterprise Value (EV)	5,326	5,563	2,095	5,267	4,700	3,394	1,888	2,299	505	562
Market Capitalization	5,541	5,607	2,621	6,302	6,250	3,942	2,369	2,956	767	714
Book Value per Share	$4.70	$2.15	$8.60	$16.50	$26.38	$9.44	$9.53	$15.92	$7.80	$5.31
Tangible Book Value per Share	$4.70	$2.15	$8.60	$16.50	$26.38	$9.44	$9.53	$15.92	$7.80	$5.31
Total Capital	948	854	1,067	971	1,470	464	432	640	220	155
Total Debt	649	723	552	0.00	0.00	0.00	13	16	6.86	11
Total Long-Term Debt	605	693	535	0.00	0.00	0.00	13	15	4.31	7.44
Net Debt	-215	-44	-526	-1,035	-1,550	-548	-481	-657	-261	-152
Capital Expenditures (CapEx)	4.63	16	8.92	3.09	3.16	14	13	16	2.35	4.88
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-90	-87	-65	-73	-75	-73	-55	-29	-20	-7.78
Debt-free Net Working Capital (DFNWC)	526	624	880	404	797	410	439	644	194	155
Net Working Capital (NWC)	482	593	863	404	797	410	439	643	192	152
Net Nonoperating Expense (NNE)	-81	167	181	195	-6.21	95	64	42	22	17
Net Nonoperating Obligations (NNO)	-215	-44	-526	-1,035	-1,550	-548	-481	-657	-263	-153
Total Depreciation and Amortization (D&A)	-6.17	-5.80	11	7.84	6.56	5.26	4.25	1.58	1.58	1.06
Debt-free, Cash-free Net Working Capital to Revenue	-17.63%	-34.84%	-31.72%	-40.46%	-9.44%	-110.13%	-122.52%	-136.39%	-70.92%	-68.28%
Debt-free Net Working Capital to Revenue	103.34%	250.12%	431.43%	224.49%	100.41%	616.89%	987.09%	3,006.31%	700.22%	1,360.02%
Net Working Capital to Revenue	94.71%	237.98%	423.17%	224.49%	100.41%	616.89%	987.09%	2,999.23%	691.03%	1,331.37%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.07)	($8.37)	($9.35)	($11.01)	$5.76	($7.27)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	62.86M	60.56M	59.64M	58.52M	54.53M	54.03M	0.00	0.00	0.00	0.00
Adjusted Diluted Earnings per Share	($1.07)	($8.37)	($9.35)	($11.01)	$5.59	($7.27)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	62.86M	60.56M	59.64M	58.52M	56.17M	54.03M	0.00	0.00	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	($7.27)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	63.91M	61.23M	59.98M	59.20K	57.96M	47.83M	0.00	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-148	-340	-376	-449	308	-253	-173	-106	-51	-36
Normalized NOPAT Margin	-29.17%	-136.50%	-184.41%	-249.55%	38.76%	-380.27%	-388.40%	-494.13%	-182.93%	-317.11%
Pre Tax Income Margin	-12.94%	-202.91%	-270.68%	-356.00%	39.68%	-522.75%	-531.53%	-691.31%	-261.04%	-462.89%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-153.57	-74.82
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-108.32	-51.94
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-158.59	-81.83
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-113.34	-58.96
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.65%	-0.20%	-3.88%

This table displays calculated financial ratios and metrics derived from Blueprint Medicines' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	55.45%	103.41%	126.61%	139.98%	51.87%	85.55%	-14.26%	57.52%	0.89%	-63.76%	172.77%
EBITDA Growth	113.37%	61.40%	61.55%	64.99%	35.34%	23.11%	-8.19%	17.23%	-16.52%	54.52%	-5.39%
EBIT Growth	112.00%	61.02%	62.70%	66.53%	36.34%	28.77%	-4.70%	18.09%	-15.97%	53.12%	-5.32%
NOPAT Growth	79.84%	60.80%	62.03%	66.37%	9.52%	29.83%	-3.78%	18.81%	-17.39%	52.62%	-6.13%
Net Income Growth	-99.44%	54.96%	57.91%	62.35%	168.80%	30.08%	-0.41%	16.85%	-22.23%	50.22%	-13.58%
EPS Growth	-99.29%	57.38%	59.55%	63.47%	165.12%	30.94%	1.35%	18.28%	-20.11%	51.20%	-11.50%
Operating Cash Flow Growth	46.33%	62.80%	86.95%	63.16%	17.44%	34.99%	19.56%	-10.33%	7.36%	-760.17%	-35.87%
Free Cash Flow Firm Growth	126.41%	84.61%	89.18%	65.18%	49.02%	-9.28%	-65.92%	43.81%	-110.07%	33.72%	-72.71%
Invested Capital Growth	-36.21%	-2.80%	-11.89%	13.73%	21.32%	840.80%	1,051.14%	57.91%	918.61%	81.74%	76.86%
Revenue Q/Q Growth	2.08%	14.19%	-7.22%	43.74%	33.57%	27.21%	-1.74%	-9.03%	63.19%	-41.22%	80.53%
EBITDA Q/Q Growth	124.81%	16.45%	-12.83%	42.82%	28.40%	16.77%	-2.75%	-5.60%	14.85%	-17.11%	21.39%
EBIT Q/Q Growth	122.85%	14.85%	-12.41%	45.13%	25.77%	18.52%	-0.86%	-4.37%	16.95%	-19.77%	21.10%
NOPAT Q/Q Growth	45.01%	15.87%	-13.77%	61.70%	-6.92%	18.51%	-0.78%	-3.04%	17.08%	-20.54%	21.16%
Net Income Q/Q Growth	100.99%	11.23%	-12.57%	-156.09%	180.36%	17.05%	-0.69%	-2.50%	18.33%	-19.14%	16.62%
EPS Q/Q Growth	101.28%	12.36%	-11.25%	-157.14%	176.50%	16.82%	-0.46%	-1.86%	18.87%	-18.83%	16.79%
Operating Cash Flow Q/Q Growth	-85.53%	-115.33%	71.63%	52.64%	-28.61%	24.46%	19.92%	-6.11%	-1.28%	6.53%	-9.84%
Free Cash Flow Firm Q/Q Growth	199.02%	-19.80%	51.31%	54.26%	-10.16%	15.81%	-56.69%	33.02%	-23.67%	-27.83%	46.94%
Invested Capital Q/Q Growth	-11.89%	-7.26%	-27.95%	8.34%	2,380.70%	-15.93%	-7.00%	15.57%	919.88%	-7.94%	-115.44%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	98.12%	94.91%	98.49%	94.50%	96.68%	99.64%	95.08%	95.96%	94.98%	87.50%	95.45%
EBITDA Margin	7.05%	-29.03%	-39.68%	-32.63%	-82.02%	-153.00%	-233.84%	-223.62%	-192.64%	-369.20%	-185.31%
Operating Margin	-27.50%	-28.15%	-38.21%	-31.16%	-82.01%	-146.07%	-228.02%	-222.31%	-196.26%	-386.27%	-188.36%
EBIT Margin	6.30%	-28.15%	-37.75%	-31.16%	-81.62%	-146.88%	-229.30%	-223.39%	-194.70%	-382.58%	-187.76%
Profit (Net Income) Margin	0.33%	-34.13%	-43.90%	-36.19%	92.74%	-154.14%	-236.38%	-230.66%	-204.72%	-409.08%	-201.83%
Tax Burden Percent	38.60%	101.36%	100.49%	100.20%	99.80%	100.06%	100.15%	100.14%	100.40%	100.66%	100.67%
Interest Burden Percent	13.65%	119.62%	115.74%	115.90%	-113.86%	104.89%	102.94%	103.11%	104.72%	106.23%	106.78%
Effective Tax Rate	61.40%	0.00%	0.00%	0.00%	0.20%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-62.78%	-117.65%	-120.15%	-66.98%	-218.20%	-682.14%	-750.19%	-388.90%	-669.46%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-69.85%	-101.34%	-106.50%	-56.92%	-283.58%	-669.05%	-738.62%	-379.07%	-662.43%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	49.51%	61.10%	66.57%	35.62%	200.78%	591.54%	658.01%	314.43%	619.51%	0.00%	0.00%
Return on Equity (ROE)	-13.27%	-56.55%	-53.58%	-31.36%	-17.43%	-90.61%	-92.18%	-74.47%	-49.95%	-75.07%	-76.04%
Cash Return on Invested Capital (CROIC)	-84.17%	-171.34%	-187.12%	-223.77%	-310.83%	-507.34%	-472.04%	-452.97%	-519.04%	0.00%	0.00%
Operating Return on Assets (OROA)	3.17%	-12.85%	-14.23%	-9.79%	-20.39%	-30.53%	-38.68%	-43.85%	-33.71%	-60.00%	-34.83%
Return on Assets (ROA)	0.17%	-15.58%	-16.55%	-11.37%	23.17%	-32.05%	-39.87%	-45.28%	-35.44%	-64.15%	-37.44%
Return on Common Equity (ROCE)	-13.27%	-56.55%	-53.58%	-31.36%	-17.43%	-90.61%	-92.18%	-74.47%	-49.95%	-75.07%	-76.04%
Return on Equity Simple (ROE_SIMPLE)	-45.52%	0.00%	-40.89%	-64.17%	-92.79%	0.00%	-273.78%	-178.11%	-140.26%	0.00%	-112.06%
Net Operating Profit after Tax (NOPAT)	-16	-29	-34	-30	-79	-74	-90	-90	-87	-105	-87
NOPAT Margin	-10.61%	-19.70%	-26.74%	-21.81%	-81.84%	-102.25%	-159.61%	-155.61%	-137.38%	-270.39%	-131.85%
Net Nonoperating Expense Percent (NNEP)	7.07%	-16.31%	-13.65%	-10.05%	65.38%	-13.09%	-11.57%	-9.84%	-7.03%	-6.89%	-4.75%
Return On Investment Capital (ROIC_SIMPLE)	-1.63%	-3.04%	-	-	-	-8.62%	-	-	-	-9.83%	-
Cost of Revenue to Revenue	1.88%	5.09%	1.51%	5.50%	3.32%	0.36%	4.92%	4.04%	5.02%	12.50%	4.55%
SG&A Expenses to Revenue	64.12%	65.90%	70.15%	64.66%	86.93%	113.29%	125.06%	124.95%	112.11%	165.08%	87.32%
R&D to Revenue	61.50%	57.17%	66.55%	61.00%	91.75%	132.48%	194.91%	191.18%	177.09%	303.86%	193.98%
Operating Expenses to Revenue	125.62%	123.06%	136.70%	125.66%	178.69%	245.71%	323.10%	318.27%	291.24%	473.77%	283.82%
Earnings before Interest and Taxes (EBIT)	9.41	-41	-48	-43	-78	-106	-130	-129	-123	-148	-124
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	11	-42	-51	-45	-79	-110	-132	-129	-122	-143	-122
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	16.53	18.55	18.71	21.07	18.56	42.93	15.04	12.28	6.51	5.09	6.15
Price to Tangible Book Value (P/TBV)	16.53	18.55	18.71	21.07	18.56	42.93	15.04	12.28	6.51	5.09	6.15
Price to Revenue (P/Rev)	10.06	10.89	13.49	18.60	20.43	22.48	14.09	16.94	13.19	12.85	14.45
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	72.79	63.40	62.23	52.13	48.01	64.37	28.66	32.75	24.88	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	9.59	10.47	12.98	18.07	19.74	22.31	13.63	16.05	11.63	10.27	12.06
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.85	2.17	2.11	2.10	1.74	5.54	3.59	2.04	1.55	1.07	0.85
Long-Term Debt to Equity	1.72	2.03	1.96	1.95	1.64	5.30	3.44	1.99	1.51	1.04	0.82
Financial Leverage	-0.71	-0.60	-0.63	-0.63	-0.71	-0.88	-0.89	-0.83	-0.94	-1.05	-1.03
Leverage Ratio	3.42	5.19	4.47	3.66	3.12	3.72	3.04	2.17	1.82	1.75	1.56
Compound Leverage Factor	0.47	6.21	5.17	4.24	-3.55	3.90	3.13	2.24	1.91	1.86	1.66
Debt to Total Capital	64.87%	68.49%	67.81%	67.79%	63.52%	84.70%	78.21%	67.15%	60.80%	51.76%	45.82%
Short-Term Debt to Total Capital	4.50%	4.63%	4.63%	4.85%	3.54%	3.55%	3.25%	1.89%	1.64%	1.58%	1.29%
Long-Term Debt to Total Capital	60.37%	63.86%	63.19%	62.93%	59.98%	81.15%	74.97%	65.26%	59.16%	50.18%	44.53%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	35.13%	31.51%	32.19%	32.21%	36.48%	15.30%	21.79%	32.85%	39.20%	48.24%	54.18%
Debt to EBITDA	-3.53	-2.98	-2.32	-1.84	-1.20	-1.47	-1.38	-1.25	-1.19	-1.05	-0.78
Net Debt to EBITDA	1.50	0.98	0.78	0.53	0.43	0.09	0.19	0.39	0.59	1.00	0.93
Long-Term Debt to EBITDA	-3.28	-2.77	-2.16	-1.71	-1.14	-1.41	-1.33	-1.22	-1.16	-1.02	-0.75
Debt to NOPAT	-5.18	-4.37	-3.42	-2.70	-1.75	-2.12	-1.96	-1.73	-1.65	-1.47	-1.10
Net Debt to NOPAT	2.20	1.45	1.15	0.78	0.63	0.13	0.27	0.54	0.82	1.40	1.32
Long-Term Debt to NOPAT	-4.82	-4.08	-3.18	-2.51	-1.66	-2.04	-1.88	-1.68	-1.61	-1.42	-1.07
Altman Z-Score	2.11	1.72	2.04	2.75	2.40	1.12	-0.33	0.75	0.31	0.54	2.05
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.80	2.85	3.32	3.71	3.76	3.76	4.09	4.80	5.21	5.71	6.99
Quick Ratio	2.61	2.65	3.10	3.48	3.43	3.51	3.82	4.50	4.94	5.29	6.59
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	26	-26	-22	-45	-99	-172	-204	-130	-194	-157	-123
Operating Cash Flow to CapEx	-2,975.37%	-3,150.64%	-54,548.00%	-1,871.23%	-9,195.02%	-1,689.02%	-1,671.46%	-5,108.65%	-4,758.55%	-8,197.50%	-3,483.24%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.39	0.00	-14.64
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-21.13	0.00	-15.47
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-21.58	0.00	-15.91
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.50	0.46	0.38	0.31	0.25	0.21	0.17	0.20	0.17	0.16	0.19
Accounts Receivable Turnover	8.14	8.58	8.11	5.88	6.18	7.52	7.14	6.67	6.81	8.38	14.44
Inventory Turnover	0.90	1.16	0.90	0.87	0.35	0.34	0.51	0.51	0.67	0.69	0.79
Fixed Asset Turnover	14.41	12.96	11.07	9.41	7.46	6.62	5.84	6.45	6.31	6.37	8.42
Accounts Payable Turnover	6.91	3.51	2.22	2.34	1.10	2.30	2.35	1.21	1.12	3.22	2.98
Days Sales Outstanding (DSO)	44.85	42.55	44.98	62.04	59.07	48.56	51.13	54.74	53.58	43.54	25.28
Days Inventory Outstanding (DIO)	405.10	315.29	407.66	419.82	1,033.68	1,088.16	718.85	717.50	546.80	527.78	461.04
Days Payable Outstanding (DPO)	52.85	104.09	164.26	156.25	330.38	158.97	155.64	301.28	327.21	113.33	122.61
Cash Conversion Cycle (CCC)	397.10	253.75	288.38	325.61	762.37	977.75	614.34	470.97	273.16	457.99	363.71
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	74	84	91	126	116	86	103	111	96	-12	-11
Invested Capital Turnover	5.91	5.97	4.49	3.07	2.67	6.67	4.70	2.50	4.87	-5.40	-9.47
Increase / (Decrease) in Invested Capital	-42	-2.42	-12	15	20	98	114	41	107	52	36
Enterprise Value (EV)	5,388	5,326	5,637	6,554	5,572	5,563	2,947	3,621	2,380	2,095	3,284
Market Capitalization	5,656	5,541	5,859	6,749	5,767	5,607	3,047	3,822	2,699	2,621	3,935
Book Value per Share	$5.35	$4.70	$4.94	$5.11	$5.05	$2.15	$3.34	$5.15	$6.91	$8.60	$10.72
Tangible Book Value per Share	$5.35	$4.70	$4.94	$5.11	$5.05	$2.15	$3.34	$5.15	$6.91	$8.60	$10.72
Total Capital	974	948	973	994	852	854	930	947	1,057	1,067	1,182
Total Debt	632	649	660	674	541	723	727	636	643	552	542
Total Long-Term Debt	588	605	615	626	511	693	697	618	625	535	526
Net Debt	-268	-215	-223	-195	-195	-44	-100	-201	-319	-526	-651
Capital Expenditures (CapEx)	1.83	0.93	0.03	2.57	1.10	4.67	6.25	2.55	2.58	1.48	3.73
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-81	-90	-92	-56	-48	-87	-72	-62	-77	-65	-70
Debt-free Net Working Capital (DFNWC)	495	526	642	708	600	624	641	660	745	880	1,067
Net Working Capital (NWC)	451	482	597	660	570	593	611	642	728	863	1,052
Net Nonoperating Expense (NNE)	-16	21	22	20	-168	37	43	43	43	54	46
Net Nonoperating Obligations (NNO)	-268	-215	-223	-195	-195	-44	-100	-201	-319	-526	-651
Total Depreciation and Amortization (D&A)	1.13	-1.29	-2.47	-2.03	-0.38	-4.41	-2.57	-0.13	1.30	5.19	1.62
Debt-free, Cash-free Net Working Capital to Revenue	-14.40%	-17.63%	-21.17%	-15.33%	-16.91%	-34.84%	-33.29%	-27.69%	-37.69%	-31.72%	-25.53%
Debt-free Net Working Capital to Revenue	88.11%	103.34%	147.84%	195.15%	212.67%	250.12%	296.48%	292.61%	364.16%	431.43%	392.05%
Net Working Capital to Revenue	80.32%	94.71%	137.47%	181.85%	201.98%	237.98%	282.51%	284.69%	355.66%	423.17%	386.43%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.01	($0.83)	($0.89)	($0.80)	$1.45	($1.83)	($2.20)	($2.19)	($2.15)	($2.65)	($2.23)
Adjusted Weighted Average Basic Shares Outstanding	64.10M	62.86M	63.38M	62.85M	61.58M	60.56M	60.69M	60.52M	60.13M	59.64M	59.76M
Adjusted Diluted Earnings per Share	$0.01	($0.78)	($0.89)	($0.80)	$1.40	($1.83)	($2.20)	($2.19)	($2.15)	($2.65)	($2.23)
Adjusted Weighted Average Diluted Shares Outstanding	66.53M	62.86M	63.38M	62.85M	63.80M	60.56M	60.69M	60.52M	60.13M	59.64M	59.76M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	64.58M	63.91M	63.53M	63.35M	62.62M	61.23M	60.79M	60.66M	60.47M	59.98M	59.83M
Normalized Net Operating Profit after Tax (NOPAT)	-29	-29	-34	-30	-79	-74	-90	-90	-87	-105	-87
Normalized NOPAT Margin	-19.25%	-19.70%	-26.74%	-21.81%	-81.84%	-102.25%	-159.61%	-155.61%	-137.38%	-270.39%	-131.85%
Pre Tax Income Margin	0.86%	-33.67%	-43.69%	-36.11%	92.93%	-154.06%	-236.04%	-230.33%	-203.90%	-406.41%	-200.49%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-21.18	0.00	-14.75
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-14.94	0.00	-10.36
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-21.62	0.00	-15.20
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-15.39	0.00	-10.81
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Blueprint Medicines' Financials

When does Blueprint Medicines's fiscal year end?

According to the most recent income statement we have on file, Blueprint Medicines' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Blueprint Medicines' net income changed over the last 9 years?

Blueprint Medicines' net income appears to be on an upward trend, with a most recent value of -$67.09 million in 2024, rising from -$52.77 million in 2015. The previous period was -$506.98 million in 2023. Find out what analysts predict for Blueprint Medicines in the coming months.

What is Blueprint Medicines's operating income?

Blueprint Medicines's total operating income in 2024 was -$212.04 million, based on the following breakdown:

Total Gross Profit: $488.66 million
Total Operating Expenses: $700.71 million

How has Blueprint Medicines revenue changed over the last 9 years?

Over the last 9 years, Blueprint Medicines' total revenue changed from $11.40 million in 2015 to $508.82 million in 2024, a change of 4,363.4%.

How much debt does Blueprint Medicines have?

Blueprint Medicines' total liabilities were at $881.15 million at the end of 2024, a 4.1% decrease from 2023, and a 2,423.4% increase since 2015.

How much cash does Blueprint Medicines have?

In the past 9 years, Blueprint Medicines' cash and equivalents has ranged from $52.07 million in 2016 to $684.64 million in 2020, and is currently $102.01 million as of their latest financial filing in 2024.

How has Blueprint Medicines' book value per share changed over the last 9 years?

Over the last 9 years, Blueprint Medicines' book value per share changed from 5.31 in 2015 to 4.70 in 2024, a change of -11.5%.

Related Companies

This page (NASDAQ:BPMC) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blueprint Medicines (BPMC) Financials

Frequently Asked Questions About Blueprint Medicines' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Blueprint Medicines (BPMC) Financials

Annual Income Statements for Blueprint Medicines

Quarterly Income Statements for Blueprint Medicines

Annual Cash Flow Statements for Blueprint Medicines

Quarterly Cash Flow Statements for Blueprint Medicines

Annual Balance Sheets for Blueprint Medicines

Quarterly Balance Sheets for Blueprint Medicines

Annual Metrics And Ratios for Blueprint Medicines

Quarterly Metrics And Ratios for Blueprint Medicines

Frequently Asked Questions About Blueprint Medicines' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools